DRD2 and schizophrenia: Amisulpride is approved in Europe as a treatment for schizophrenia because of its ability to potently and specifically inhibit D2R signaling, resulting in a decrease in dopamine signaling, and its effects have been well studied in humans and mice.32 Based on our in vitro studies, we hypothesized that in vivo administration of amisulpride at the therapeutic dosage of 10 mg/kg could reverse the diabetic bone phenotype seen in our mouse model.